Lenalidomide Capsule
NDC Package 82293-036-10

11-digit billing NDC: 82293003610
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Lenalidomide capsules is  in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).Lenalidomide capsules are indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). This formulation utilizes a capsule delivery system. Marketed by Novugen Pharma (usa) Llc, this product is identified by NDC 82293-036 and is authorized under FDA application ANDA217281.

Identification & Billing

NDC Package Code
82293-036-10
Package Description
28 CAPSULE in 1 BOTTLE
Product Code
82293-036
11-Digit Billing Format
82293003610

Clinical Specifications

Proprietary Name
Lenalidomide
Non-Proprietary Name
Lenalidomide
Substance Name
Lenalidomide
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
LENALIDOMIDE 10 mg/1
Pharmacologic Class
Thalidomide Analog - [EPC] (Established Pharmacologic Class)
Usage Information
Lenalidomide capsules in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).Lenalidomide capsules are indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).

Regulatory & Marketing

Labeler Name
Novugen Pharma (usa) Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA217281
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-10-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 82293-036-10 identifies a specific commercial package of 28 capsule in 1 bottle of Lenalidomide, a human prescription drug labeled by Novugen Pharma (usa) Llc. This capsule is formulated for oral use and contains lenalidomide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novugen Pharma (usa) Llc on April 10, 2026. The current certification is valid through December 31, 2027.

How is this Novugen Pharma (usa) Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 82293003610. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
82293-036-10
11-Digit CMS (5-4-2)
82293-0036-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.